GH-axis peptides and the IGF-1 longevity paradox
The GH axis presents one of the more genuine paradoxes in longevity biology. On one hand, GH and IGF-1 output decline progressively across adulthood — the somatopause — and this decline is associated with measurable changes in body composition, sleep architecture and recovery capacity. GHRH-analogue and GHRP peptides (sermorelin, CJC-1295, Ipamorelin) reliably restore IGF-1 profiles toward those of younger adults in pilot studies.
On the other hand, lower IGF-1 levels are associated with longer lifespan in multiple animal models. Ames dwarf mice, Snell dwarf mice and GH-receptor-knockout mice all show substantial lifespan extension associated with reduced IGF-1 signalling. In humans, the Laron-syndrome population (GH-receptor-deficient, near-zero IGF-1) shows striking reductions in cancer and diabetes incidence, although whole-population lifespan effects are confounded by other phenotypic features.
How do we reconcile these observations? Three interpretations have been offered. First: the comparison is across different ageing models. Restoring IGF-1 in a 60-year-old human is not the same as constitutively low IGF-1 from birth in a dwarf mouse — developmental and adult-window effects may differ.
Second: feedback-preserved pharmacology may matter. GHRH analogues stimulate the pituitary to release endogenous GH in pulses subject to normal IGF-1 negative feedback. This is mechanistically distinct from sustained recombinant GH supplementation, which produces non-physiological IGF-1 elevation with no feedback regulation. Whether the difference translates into different long-term consequences is not established.
Third: short-term benefits may outweigh long-term costs in a useful window. Body-composition, sleep-architecture and quality-of-life improvements in older adults may produce healthspan benefits that outweigh any small lifespan cost — though this is not directly supported by long-term data.
The honest summary in 2026 is that the longevity-biology case for GH-axis restoration in older adults remains contested. The case for body-composition, sleep and quality-of-life applications is more straightforward; the case for lifespan is not.